Armata Pharmaceuticals Enters Capital Sales Agreement

Armata Pharmaceuticals ( (ARMP) ) has shared an announcement.

On December 1, 2025, Armata Pharmaceuticals entered into a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC. This agreement allows Armata to offer and sell up to $100 million in common stock through an at-the-market offering program. The sales will be conducted by Jones as the sales agent, with Armata paying a commission of up to 3% on gross sales proceeds. This strategic move aims to bolster Armata’s financial flexibility and enhance its market presence, potentially impacting its operations and stakeholder interests.

The most recent analyst rating on (ARMP) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Armata Pharmaceuticals stock, see the ARMP Stock Forecast page.

Spark’s Take on ARMP Stock

According to Spark, TipRanks’ AI Analyst, ARMP is a Neutral.

The overall stock score for Armata Pharmaceuticals is primarily impacted by its poor financial performance, which is a significant concern. While technical analysis shows positive momentum, the valuation remains unattractive due to negative earnings. The absence of earnings call data and corporate events means these factors do not influence the score.

To see Spark’s full report on ARMP stock, click here.

More about Armata Pharmaceuticals

Armata Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative therapies. The company primarily engages in creating bacteriophage-based treatments aimed at combating antibiotic-resistant infections.

Average Trading Volume: 273,240

Technical Sentiment Signal: Buy

Current Market Cap: $266.3M

For detailed information about ARMP stock, go to TipRanks’ Stock Analysis page.